Orexo's share is listed on NasdaqOMX Stockholm, Sweden (ORX), and is available as American Depository Receipts on OTCQX market in the US (OXROY).
Share price
Name
0.00
0 SEK (0%)
HH:MM CET • 20YY-MM-DD
Latest presentations
Analyst reports
Investment themes
Latest CEO Comments
APRIL 28, 2022
"Promising start to 2022"
Read the latest CEO comments from Nikolaj Sørensen
News flow
Press Releases and News
One Pill Can Kill – Fentanyl Awareness Day May 10
Orexo´s partner Gesynta Pharma granted Orphan Drug Designation by the FDA for OX-MPI (GS-248) for the treatment of systemic sclerosis
Orexo appoints Fredrik Järrsten as new CFO
Orexo's lead product ZUBSOLV® added to NY State Medicaid MAT Preferred Drug List
Key financial figures
Group net revenue
592 MSEK
Last Twelve Months, Q221-Q122
Group EBITDA
-134 MSEK
Last Twelve Months, Q221-Q122
US Pharma segment EBIT
296 MSEK
Last Twelve Months, Q221-Q122
Cash position
434 MSEK
Q122
